高级检索
当前位置: 首页 > 详情页

Gut and obesity/metabolic disease: Focus on microbiota metabolites

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ ESCI

机构: [1]State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy West China Hospital Sichuan University Chengdu China. [2]Guangdong Institute of Gastroenterology Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Disease Sixth Affiliated Hospital of Sun Yat-Sen University Guangzhou China. [3]Department of Colorectal Surgery Sixth Affiliated Hospital Sun Yat-Sen University Guangzhou China.
出处:

摘要:
Obesity is often associated with the risk of chronic inflammation and other metabolic diseases, such as diabetes, cardiovascular disease, and cancer. The composition and activity of the gut microbiota play an important role in this process, affecting a range of physiological processes, such as nutrient absorption and energy metabolism. The active gut microbiota can produce a large number of physiologically active substances during the process of intestinal metabolism and reproduction, including short-chain/long-chain fatty acids, secondary bile acids, and tryptophan metabolites with beneficial effects on metabolism, as well as negative metabolites, including trimethylamine N-oxide, delta-valerobetaine, and imidazole propionate. How gut microbiota specifically affect and participate in metabolic and immune activities, especially the metabolites directly produced by gut microbiota, has attracted extensive attention. So far, some animal and human studies have shown that gut microbiota metabolites are correlated with host obesity, energy metabolism, and inflammation. Some pathways and mechanisms are slowly being discovered. Here, we will focus on the important metabolites of gut microbiota (beneficial and negative), and review their roles and mechanisms in obesity and related metabolic diseases, hoping to provide a new perspective for the treatment and remission of obesity and other metabolic diseases from the perspective of metabolites.© 2022 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
最新[2023]版:
大类 | 3 区 医学
小类 | 3 区 医学:研究与实验
JCR分区:
出版当年[2022]版:
最新[2023]版:
Q1 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者:
第一作者机构: [1]State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy West China Hospital Sichuan University Chengdu China.
通讯作者:
通讯机构: [1]State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy West China Hospital Sichuan University Chengdu China. [*1]State Key Laboratory of Biotherapy and Cancer Center/Collaborative Innovation Center for Biotherapy,West China Hospital, Sichuan University, Chengdu 610041, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43375 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号